4SC gets a confidence boost in clinic and stockmarket
Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a clinical Phase II study with the cancer drug resminostat as a second-line therapy for patients with advanced liver cancer (hepatocellular carcinoma, HCC) which has reached its primary endpoint well ahead of schedule. This open-label, two-arm,international study investigated the safety and efficacy of resminostat both as a monotherapy and in combination with sorafenib. All patients had exhibited radiologically proven tumour progression under first-line therapy with sorafenib prior to study entry. According to the data now presented, the compound managed to halt the further progression of this relatively aggressive cancer in at least 20% of the patients treated and for at least 12 weeks. In 2011 Resminostat already proved its efficacy in patients with non Hodgkin's Lymphoma. Now the hopes are high in Munich that a comprehensive approval of Resminostat is on the horizon.